1 day Ago By ABMN Staff
Allurion Technologies Inc. ( NYSE:ALUR – Get Free Report ) was the target of a large growth in short interest in August. As of August 31st, there was short interest totalling 571,400 shares, a growth of 8.
6% from the August 15th total of 526,300 shares. Currently, 1.2% of the shares of the stock are sold short.
Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is currently 0.4 days. Allurion Technologies Stock Up 8.
6 % NYSE:ALUR traded up $0.05 during mid-day trading on Wednesday, reaching $0.64.
97,961 shares of the company were exchanged, compared to its average volume of 856,394. The stock has a market cap of $30.72 million, a PE ratio of -0.
17 and a beta of -0.33. Allurion Technologies has a 12 month low of $0.
55 and a 12 month high of $6.43. The company has a fifty day moving average of $0.
75 and a 200 day moving average of $1.49. Allurion Technologies ( NYSE:ALUR – Get Free Report ) last released its quarterly earnings results on Tuesday, August 13th.
The company reported $0.01 EPS for the quarter. The company had revenue of $11.
77 million for the quarter. On average, equities research analysts anticipate that Allurion Technologies will post -0.3 EPS for the current fiscal year.
Institutional Inflows and Outflows Wall Street Analyst Weigh In A number of equities analysts have commented on the stock. Roth Capital upgraded shares of Allurion Technologies to a “strong-buy” rating in a research report on Friday, September 6th. Roth Mkm started coverage on Allurion Technologies in a report on Friday, September 6th.
They issued a “buy” rating and a $2.00 target price on the stock. Finally, Chardan Capital decreased their price target on Allurion Technologies from $5.
00 to $2.50 and set a “buy” rating on the stock in a research report on Thursday, August 22nd. Get Our Latest Report on Allurion Technologies About Allurion Technologies ( Get Free Report ) Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight.
Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Featured Articles Receive News & Ratings for Allurion Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allurion Technologies and related companies with MarketBeat.com's FREE daily email newsletter .
.
